Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmonary-Allergy Drugs

Executive Summary

At July 23 meeting, the FDA Advisory Committee will discuss two lung surfactant extracts: Burroughs Wellcome's synthetic extract Exosurf (colfosceril palmitate) and Survanta (beractant), a bovine lung surfactant TA from Abbott's Ross Labs subsidiary. Both products are currently available under Treatment INDs for respiratory distress syndrome in premature infants (also called hyaline membrane disease), an orphan indication. Exosurf received a Treatment IND in July 1989; Survanta in October 1989.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel